Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Early-Onset Preeclampsia Risk Reflected in Circulating Maternal Transcripts

By LabMedica International staff writers
Posted on 13 Jul 2020
Preeclampsia is a poorly understood pregnancy-associated disorder. More...
Often marked by hypertension, preeclampsia can lead to severe complications including internal bleeding, seizures, stroke, premature birth, and death.

Preeclampsia can develop suddenly, and identifying who is at risk of the condition is difficult. Circulating RNA (C-RNA) is continually released into the bloodstream from tissues throughout the body, offering an opportunity to noninvasively monitor all aspects of pregnancy health from conception to birth.

A team of scientists led by those at Illumina (San Diego, CA, USA) used transcriptome enrichment and sequencing to search for preeclampsia-related RNAs in blood samples collected over time from more than 100 pregnant women with or without early-onset preeclampsia, a condition linked to a rise in maternal and perinatal morbidity and mortality risk. They sequenced the circulating transcriptome from 40 pregnancies at the time of severe, early-onset preeclampsia diagnosis and 73 gestational age–matched controls.

The investigators saw more than three-dozen suspicious transcripts with enhanced representation in blood plasma from the preeclampsia pregnancies, focusing in on 30 preeclampsia-related circulating transcripts with follow-up quantitative polymerase chain reaction (PCR) and validation analyses.

The team brought in machine learning classifier clues, and they acquired a set of 49 circulating RNA transcripts that could pick up early-onset preeclampsia pregnancies with between 85% and 89% accuracy, on average, in another group of two dozen women with or without preeclampsia. The average accuracy of the circulating RNA-based classifier dipped to around 72% for women in the validation cohort experiencing late-onset preeclampsia. Differential expression analysis identified the 30 transcripts with gene ontology annotations and tissue expression patterns consistent with the placental dysfunction, impaired fetal development, and maternal immune and cardiovascular system dysregulation characteristic of preeclampsia.

The authors concluded that they had detected molecular changes specific to the complex pathophysiology of early-onset severe preeclampsia at the time of diagnosis, supporting robust classification across cohorts. They noted that the altered circulating RNA transcripts identified represented contributions from maternal, placental, and fetal tissues, many of which would not be captured in studies focusing on placental tissues collected after delivery. The study was published on July 1, 2020 in the journal Science Translational Medicine.



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.